Molecular monitoring in malaria vaccine trials

Trends in Parasitology

Volumn 19, Issue 2, 2003, Pages 60-63

  Felger, Ingrid ^a   Genton, Blaise ^a   Smith, Tom ^a   Tanner, Marcel ^a   Beck, Hans Peter ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIPARASITIC AGENT; MALARIA VACCINE; MEFLOQUINE; PROTEIN SPF66; PYRIMETHAMINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HUMAN; INCIDENCE; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; SIDE EFFECT;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0037314490     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(02)00066-1     Document Type: Short Survey

References (27)

1. Barker R.H., et al. Plasmodium falciparum and P. vivax: factors affecting sensitivity and specificity of PCR-based diagnosis of malaria. Exp. Parasitol. 79:1994;41-49.
2. Snounou G., et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol. Biochem. Parasitol. 61:1993;315-320.
3. Brockman A., et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am. J. Trop. Med. Hyg. 60:1999;14-21.
4. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase I/IIb trial in Papua New Guinea. J. Infect. Dis. 185:2002;820-827.
5. Cheng Q., et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg. 57:1997;495-500.
6. Lawrence G., et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 18:2000;1925-1931.
7. Hermsen C.C., et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol. Biochem. Parasitol. 118:2001;247-251.
8. Witney A.A., et al. Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Mol. Biochem. Parasitol. 118:2001;233-245.
9. Smith T., et al. Effect of insecticide-treated bed nets on the dynamics of multiple Plasmodium falciparum infections. Trans. R. Soc. Trop. Med. Hyg. 93 (Suppl 1):1999;53-57.
10. Smith, T. and Vounatsou, P. Estimation of infection and recovery rates for highly polymorphic parasites when detectability is imperfect, using hidden Markov models. Stat. Med. (in press).
11. Fraser-Hurt N., et al. Effect of insecticide-treated bed nets on haemoglobin values, prevalence and multiplicity of infection with Plasmodium falciparum in a randomized controlled trial in Tanzania. Trans. R. Soc. Trop. Med. Hyg. 93 (Suppl 1):1999;47-51.
12. Coulibaly, D. et al. Impact of pre-season treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara. Mali. Am. J. Trop. Med. Hyg. (in press).
13. Owusu-Agyei S., et al. Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. Am. J. Trop. Med. Hyg. 65:2001;197-203.
14. Arnot D. Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission. Trans. R. Soc. Trop. Med. Hyg. 92:1998;580-585.
15. Alonso P.L., et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet. 344:1994;1175-1181.
16. Beck H.-P., et al. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66. J. Infect. Dis. 175:1997;921-926.
17. Haywood M., et al. Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66. Trans. R. Soc. Trop. Med. Hyg. 93 (Suppl 1):1999;65-68.
18. Doumbo O.K., et al. Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. J. Infect. Dis. 182:2000;993-996.
19. Bojang K.A., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 358:2001;1927-1934.
20. Gandon S., et al. Imperfect vaccines and the evolution of pathogen virulence. Nature. 414:2001;751-756.
21. Babiker H., et al. Genetic evidence that RI chloroquine resistance of Plasmodium falciparum is caused by recrudescence of resistant parasites. Trans. R. Soc. Trop. Med. Hyg. 88:1994;328-331.
22. Al Yaman F., et al. Evidence that recurrent Plasmodium falciparum infection is caused by recrudescence of resistant parasites. Am. J. Trop. Med. Hyg. 56:1997;436-439.
23. Ranford-Cartwright L.C., et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans. R. Soc. Trop. Med. Hyg. 91:1997;719-724.
24. von Seidlein L., et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J. Infect. Dis. 176:1997;1113-1116.
25. von Seidlein L., et al. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children. Am. J. Trop. Med. Hyg. 58:1998;638-644.
26. Irion A., et al. Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in Tanzanian children. Trop. Med. Int. Health. 3:1998;490-497.
27. Snounou G., Beck H.-P. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol. Today. 14:1998;462-467.